OS Therapies secured $7.2 million from warrant exercises by investors, providing funds to support regulatory submissions for its cancer immunotherapy Herlystic™ in the U.S., U.K., Europe, and Australia, expected in Q4 2026. The company also anticipates receiving $7 million in UK R&D tax credits by early 2027 to extend its operating runway. Herlystic™ targets osteosarcoma and has multiple FDA and EMA designations, with plans to submit a Biologics License Application and Conditional Marketing Authorisation Applications later this year. Successful approval could make OS Therapies eligible for a Priority Review Voucher, potentially generating significant revenue.
OS Therapies' recent $7.2 million warrant exercise inducement and exchange offer is noted here with Pluang's Health sector market data as of Oct 19, 2026 18:43 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 68 rose and 54 fell today. Notable movers include HIMS at USD 28.48 with a 1-day change of +1.46%, BTSG at USD 61.72 with +1.40%, and IOVA at USD 13.80 with +1.32%, with typical hold times ranging from 2 to 22 days.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
